Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743036 · ClinicalTrials.gov registry record · Phase 1
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT05743036 is a Phase 1 study that was terminated before completion, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT05743036, a Phase 1 study, was terminated before completion, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Interventions
- DRUG Cetuximab
- DRUG Encorafenib
- DRUG ZN-c3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05743036
The ClinicalTrials.gov registry entry for NCT05743036 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT05743036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05743036 about?
NCT05743036 is a clinical study titled "ZN-c3 in Adult Participants With Metastatic Colorectal Cancer". The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
What is the current status of trial NCT05743036?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-02-27. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT05743036?
The interventions under investigation include: Cetuximab (DRUG), Encorafenib (DRUG), ZN-c3 (DRUG).
Who is sponsoring clinical trial NCT05743036?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.